Danaher to Acquire Iris International for $338M | GenomeWeb

NEW YORK (GenomeWeb News) – Danaher today said that it has signed definitive agreement to acquire diagnostics and sample prep technologies firm Iris International for $19.50 per share in cash.

The total consideration being paid is $338 million including debt and net of cash acquired, said Danaher. The purchase price represents a 45 percent premium to Iris' closing stock price of $13.42 on Sept. 14.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.